Lineage begins study of OPC1 delivering device for spinal cord injury treatment
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...
PipelineReview.com18 小时
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
Safety Study of Stem Cell-derived Transplant Includes Subacute and Chronic SCI Patients. CARLSBAD, CA, USA I 11, 2025 I Lineage Cell Therapeutics, Inc. (NYSE American and ...
Lineage Cell Therapeutics’ (LCTX) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) in a report released on Tuesday morning,Benzinga reports. The firm currently has a ...